Navigation Links
University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
Date:11/20/2008

SAN DIEGO, Nov. 20 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis, manipulation and purification systems, announced today that it has entered a research collaboration agreement with the University of Florida Interdisciplinary Center for Biotechnology Research. The agreement will focus on a variety of research areas including the purification and analysis of cancer stem cells (CSCs), rare cells which are believed to be directly involved in propagating cancers. The collaboration will exploit Cyntellect's proprietary LEAP system to purify these CSCs and their progeny without disturbing them from their growing environment -- a feat that should improve scientists' ability to study the natural properties and responses of these cells. Under the agreement, University of Florida will gain access to LEAP and Cyntellect will receive certain payments and commercial rights to discoveries under the collaboration.

"We are very pleased to embark with University of Florida on this quest to gain a better understanding of the molecular machinery, signaling pathways and markers associated with rare cells, such as CSCs. This information will be paramount to innovating novel drug development strategies and developing new cutting-edge diagnostics for crippling diseases, such as cancer," stated Dr. Fred Koller, Cyntellect's Chief Executive Officer. "We believe our LEAP technology offers a truly unique, efficient and highly accurate means of isolating rare cells and making them readily available for subsequent functional, proteomic or genetic analyses."

CSCs are cancer cells (found within tumors or hematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. These cells are therefore tumorigenic (tumor-forming), perhaps in contrast to other non-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are proposed to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for sufferers of metastatic disease [Wikipedia].

The collaboration represents the Company's second major LEAP collaboration this year and follows on the heels of a publicly announced LEAP system purchase by the University of Florida McKnight Brain Institute earlier this year. Cyntellect plans to enter into additional LEAP collaborations in 2009 aimed at leveraging cell manipulation for the purpose of enhancing discovery of new drugs, empowering cell-based diagnostics and accelerating development of cellular therapies. Parties interested in being considered for such collaborations should initiate contact and submit concept proposals to Cyntellect at info@cyntellect.com.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cellular analysis and laser-based manipulation to provide products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at http://www.cyntellect.com.


'/>"/>
SOURCE Cyntellect, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
6. University of Leicester scientists discover technique to help friendly bacteria
7. MichBio Announces Student Career Day at Michigan State University
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
10. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
11. McGill University Purchases GenVaults Personal Archive System to Manage Rare Cancer Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):